Addex  Pharmaceuticals   discovers  and  develops allosteric modulators for human health. Allosteric modulators are a different kind of orally available small molecule therapeutic agent, which we believe will offer a competitive advantage over classical drugs. The lead product in our pipeline, ADX10059, has achieved clinical proof of concept and is in Phase IIb testing for the treatment of GERD (e.g. heartburn) and, separately, migraine headache. Both are important diseases for which existing products have established multi-billion dollar markets despite sub-optimal efficacy. ADX10059 is a first-in-class mGluR5 inhibitor, a therapeutic strategy that also is being pursued for multiple indications by large pharma competitors.

Our technology and products already have proven their value through our relationships with four of the top 10 pharmaceutical companies in the world. Specifically, in two separate agreements with Merck & Co., Inc., signed in December 2007 and January 2008, we are developing allosteric modulators as drugs to treat Parkinson's disease and schizophrenia, respectively. A third agreement, with Ortho-McNeil-Janssen Inc., a Johnson & Johnson company, is focused on development of allosteric modulators to treat anxiety and schizophrenia. Separately, the investment funds of Roche and GlaxoSmithKline have extended their validation of our technology, products and management by making significant investments in Addex.

 

selected press releases

2008 Annual Report: Webzine or PDF

our allosteric modulator discovery laboratories in Geneva

media and other exposure